2025-2031 Global Cas Nuclease Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Medical Care > 2025-2031 Global Cas Nuclease Industry Research & Trends Analysis Report

2025-2031 Global Cas Nuclease Industry Research & Trends Analysis Report

Publication Date: 2025-10-05
Report Id: 2491606
Industry: Medical Care
Report Page: 133
Chart: 133

PDF Download

Publication Date: 2025-10-05
Report Id: 2491606
Industry: Medical Care
Report Page: 133
Chart: 133

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Cas Nuclease
1.2 Global Cas Nuclease Market Size and Forecast
1.3 China Cas Nuclease Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Cas Nuclease Share in Global Market, 2020-2031
1.4.2 Cas Nuclease Market Size: China VS Global, 2020-2031
1.5 Cas Nuclease Market Dynamics
1.5.1 Cas Nuclease Market Drivers
1.5.2 Cas Nuclease Market Restraints
1.5.3 Cas Nuclease Industry Trends
1.5.4 Cas Nuclease Industry Policy

2 Competitive Landscape by Company
2.1 Global Cas Nuclease Revenue by Company, 2020-2025
2.2 Global Cas Nuclease Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Cas Nuclease Concentration Ratio
2.4 Global Cas Nuclease Mergers & Acquisitions, Expansion Plans
2.5 Global Cas Nuclease Manufacturers Product Type
2.6 Global Geographic Distribution of Cas Nuclease Companies

3 China Competitive Situation by Company
3.1 China Cas Nuclease Revenue by Company, 2020-2025
3.2 China Cas Nuclease Cas Nuclease Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Cas Nuclease Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Cas Nuclease Industry Chain
4.2 Cas Nuclease Upstream Analysis
4.3 Cas Nuclease Midstream Analysis
4.4 Cas Nuclease Downstream Analysis

5 Sights by Type
5.1 Cas Nuclease Classification by Type
5.1.1 Cas9
5.1.2 Cpf1
5.1.3 Cas9n
5.1.4 Others
5.2 by Type, Global Cas Nuclease Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Cas Nuclease Market Size, 2020-2031

6 Sights by Application
6.1 Cas Nuclease Segment by Application
6.1.1 Gene Editing Cell Line Construction
6.1.2 Animal Models
6.1.3 Bioagriculture
6.1.4 Gene Therapy
6.1.5 Other
6.2 by Application, Global Cas Nuclease Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Cas Nuclease Market Size, 2020-2031

7 Sights by Region
7.1 By Region, Global Cas Nuclease Market Size, 2020 VS 2024 VS 2031
7.2 By Region, Global Cas Nuclease Market Size, 2020-2031
7.3 North America
7.3.1 North America Cas Nuclease Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Cas Nuclease Market Size Market Share
7.4 Europe
7.4.1 Europe Cas Nuclease Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Cas Nuclease Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Cas Nuclease Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Cas Nuclease Market Size Market Share
7.6 South America
7.6.1 South America Cas Nuclease Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Cas Nuclease Market Size Market Share
7.7 Middle East & Africa

8 Sights by Country Level
8.1 By Country, Global Cas Nuclease Market Size & CAGR，2020 VS 2024 VS 2031
8.2 By Country, Global Cas Nuclease Market Size, 2020-2031
8.3 United States
8.3.1 United States Cas Nuclease Market Size, 2020-2031
8.3.2 By Company, United States Cas Nuclease Revenue Market Share, 2024
8.3.3 by Type, United States Cas Nuclease Revenue Market Share, 2024 VS 2031
8.3.4 by Application, United States Cas Nuclease Revenue Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Cas Nuclease Market Size, 2020-2031
8.4.2 By Company, Europe Cas Nuclease Revenue Market Share, 2024
8.4.3 by Type, Europe Cas Nuclease Revenue Market Share, 2024 VS 2031
8.4.4 by Application, Europe Cas Nuclease Revenue Market Share, 2024 VS 2031
8.5 China
8.5.1 China Cas Nuclease Market Size, 2020-2031
8.5.2 By Company, China Cas Nuclease Revenue Market Share, 2024
8.5.3 by Type, China Cas Nuclease Revenue Market Share, 2024 VS 2031
8.5.4 by Application, China Cas Nuclease Revenue Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Cas Nuclease Market Size, 2020-2031
8.6.2 By Company, Japan Cas Nuclease Revenue Market Share, 2024
8.6.3 by Type, Japan Cas Nuclease Revenue Market Share, 2024 VS 2031
8.6.4 by Application, Japan Cas Nuclease Revenue Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Cas Nuclease Market Size, 2020-2031
8.7.2 By Company, South Korea Cas Nuclease Revenue Market Share, 2024
8.7.3 by Type, South Korea Cas Nuclease Revenue Market Share, 2024 VS 2031
8.7.4 by Application, South Korea Cas Nuclease Revenue Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Cas Nuclease Market Size, 2020-2031
8.8.2 By Company, Southeast Asia Cas Nuclease Revenue Market Share, 2024
8.8.3 by Type, Southeast Asia Cas Nuclease Revenue Market Share, 2024 VS 2031
8.8.4 by Application, Southeast Asia Cas Nuclease Revenue Market Share, 2024 VS 2031
8.9 India
8.9.1 India Cas Nuclease Market Size, 2020-2031
8.9.2 By Company, India Cas Nuclease Revenue Market Share, 2024
8.9.3 by Type, India Cas Nuclease Revenue Market Share, 2024 VS 2031
8.9.4 by Application, India Cas Nuclease Revenue Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Cas Nuclease Market Size, 2020-2031
8.10.2 By Company, Middle East & Africa Cas Nuclease Revenue Market Share, 2024
8.10.3 by Type, Middle East & Africa Cas Nuclease Revenue Market Share, 2024 VS 2031
8.10.4 by Application, Middle East & Africa Cas Nuclease Revenue Market Share, 2024 VS 2031

9 Company Profile
9.1 Thermo Fisher Scientific
9.1.1 Thermo Fisher Scientific Company Information, Head Office, Market Area, and Industry Position
9.1.2 Thermo Fisher Scientific Company Profile and Main Business
9.1.3 Thermo Fisher Scientific Cas Nuclease Models, Specifications, and Application
9.1.4 Thermo Fisher Scientific Cas Nuclease Revenue and Gross Margin, 2020-2025
9.1.5 Thermo Fisher Scientific Recent Developments
9.2 GenScript
9.2.1 GenScript Company Information, Head Office, Market Area, and Industry Position
9.2.2 GenScript Company Profile and Main Business
9.2.3 GenScript Cas Nuclease Models, Specifications, and Application
9.2.4 GenScript Cas Nuclease Revenue and Gross Margin, 2020-2025
9.2.5 GenScript Recent Developments
9.3 Integrated DNA Technologies, Inc.
9.3.1 Integrated DNA Technologies, Inc. Company Information, Head Office, Market Area, and Industry Position
9.3.2 Integrated DNA Technologies, Inc. Company Profile and Main Business
9.3.3 Integrated DNA Technologies, Inc. Cas Nuclease Models, Specifications, and Application
9.3.4 Integrated DNA Technologies, Inc. Cas Nuclease Revenue and Gross Margin, 2020-2025
9.3.5 Integrated DNA Technologies, Inc. Recent Developments
9.4 Aldevron
9.4.1 Aldevron Company Information, Head Office, Market Area, and Industry Position
9.4.2 Aldevron Company Profile and Main Business
9.4.3 Aldevron Cas Nuclease Models, Specifications, and Application
9.4.4 Aldevron Cas Nuclease Revenue and Gross Margin, 2020-2025
9.4.5 Aldevron Recent Developments
9.5 Merck
9.5.1 Merck Company Information, Head Office, Market Area, and Industry Position
9.5.2 Merck Company Profile and Main Business
9.5.3 Merck Cas Nuclease Models, Specifications, and Application
9.5.4 Merck Cas Nuclease Revenue and Gross Margin, 2020-2025
9.5.5 Merck Recent Developments
9.6 Horizon Discovery
9.6.1 Horizon Discovery Company Information, Head Office, Market Area, and Industry Position
9.6.2 Horizon Discovery Company Profile and Main Business
9.6.3 Horizon Discovery Cas Nuclease Models, Specifications, and Application
9.6.4 Horizon Discovery Cas Nuclease Revenue and Gross Margin, 2020-2025
9.6.5 Horizon Discovery Recent Developments
9.7 Agilent
9.7.1 Agilent Company Information, Head Office, Market Area, and Industry Position
9.7.2 Agilent Company Profile and Main Business
9.7.3 Agilent Cas Nuclease Models, Specifications, and Application
9.7.4 Agilent Cas Nuclease Revenue and Gross Margin, 2020-2025
9.7.5 Agilent Recent Developments
9.8 OriGene Technologies, Inc
9.8.1 OriGene Technologies, Inc Company Information, Head Office, Market Area, and Industry Position
9.8.2 OriGene Technologies, Inc Company Profile and Main Business
9.8.3 OriGene Technologies, Inc Cas Nuclease Models, Specifications, and Application
9.8.4 OriGene Technologies, Inc Cas Nuclease Revenue and Gross Margin, 2020-2025
9.8.5 OriGene Technologies, Inc Recent Developments
9.9 New England Biolabs
9.9.1 New England Biolabs Company Information, Head Office, Market Area, and Industry Position
9.9.2 New England Biolabs Company Profile and Main Business
9.9.3 New England Biolabs Cas Nuclease Models, Specifications, and Application
9.9.4 New England Biolabs Cas Nuclease Revenue and Gross Margin, 2020-2025
9.9.5 New England Biolabs Recent Developments
9.10 NIPPON GENE CO., LTD.
9.10.1 NIPPON GENE CO., LTD. Company Information, Head Office, Market Area, and Industry Position
9.10.2 NIPPON GENE CO., LTD. Company Profile and Main Business
9.10.3 NIPPON GENE CO., LTD. Cas Nuclease Models, Specifications, and Application
9.10.4 NIPPON GENE CO., LTD. Cas Nuclease Revenue and Gross Margin, 2020-2025
9.10.5 NIPPON GENE CO., LTD. Recent Developments
9.11 Novoprotein
9.11.1 Novoprotein Company Information, Head Office, Market Area, and Industry Position
9.11.2 Novoprotein Company Profile and Main Business
9.11.3 Novoprotein Cas Nuclease Models, Specifications, and Application
9.11.4 Novoprotein Cas Nuclease Revenue and Gross Margin, 2020-2025
9.11.5 Novoprotein Recent Developments
9.12 Applied Biological Materials Inc. (abm)
9.12.1 Applied Biological Materials Inc. (abm) Company Information, Head Office, Market Area, and Industry Position
9.12.2 Applied Biological Materials Inc. (abm) Company Profile and Main Business
9.12.3 Applied Biological Materials Inc. (abm) Cas Nuclease Models, Specifications, and Application
9.12.4 Applied Biological Materials Inc. (abm) Cas Nuclease Revenue and Gross Margin, 2020-2025
9.12.5 Applied Biological Materials Inc. (abm) Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Cas Nuclease should grow from US$ 250 million in 2024 to US$ 1050 million by 2031, with a CAGR of 22.4% for the period of 2025-2031.

Cas nucleases are core components of the CRISPR (clustered regularly interspaced short palindromic repeats) system. They are RNA-guided endonucleases that recognize specific nucleic acid sequences through crRNA (CRISPR RNA) and catalyze the cleavage of target DNA or RNA. The industry's gross profit margin is approximately 30%-50%.

Cas Nuclease

According to YH Research, the global market for Cas Nuclease should grow from US$ 250 million in 2024 to US$ 1050 million by 2031, with a CAGR of 22.4% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The main manufacturers of Cas nuclease include Thermo Fisher Scientific, GenScript and Integrated DNA Technologies, Inc., etc. The top three manufacturers account for about 45% of the share. North America is the largest market with about 44% share, followed by Europe and China with about 35% and 8% of the market. Cas9 is the largest segment with an 85% share. Gene editing cell line construction was the largest application with about 40% share.

Market drivers primarily include the following:
Evolving biotechnology and medical needs are driving application expansion.

Demand for precision editing tools is surging in cutting-edge fields such as gene therapy and cell therapy. As core tools, the performance of Cas nucleases (such as off-target rate and cleavage efficiency) directly impacts therapeutic safety and efficacy. For example, high-fidelity Cas9 variants (such as HiFiCas9) can reduce the risk of off-target gene editing and meet clinical application standards. Furthermore, the demand for rapid and sensitive detection technologies in molecular diagnostics is driving the application of Cas12/Cas13 in point-of-care (POCT) testing, such as the SHERLOCK-based virus detection platform.

Policy support and capital investment are accelerating technology transfer.

Many governments around the world are supporting gene editing technology research and development through special funds and fast-track approvals. For example, China's 14th Five-Year Plan explicitly lists gene therapy as a strategic emerging industry, and the US FDA has launched a "Super Fund" to accelerate the approval of CRISPR therapies. Global funding for gene editing is expected to exceed US$5 billion in 2023. Leading companies (such as Intellia Therapeutics and Editas Medicine) are consolidating resources through IPOs or mergers and acquisitions to promote large-scale production and commercial application of Cas nucleases. Technological iteration and interdisciplinary integration are driving new scenarios.

Development of novel enzymes: ReChb nucleases, designed using ancestral sequence reconstruction (ASR) technology, can recognize and flexibly cleave any nucleic acid form (dsDNA, ssDNA, and ssRNA), overcoming the PAM sequence limitations of traditional Cas enzymes and providing a universal tool for gene therapy and diagnostics.

Delivery system optimization: Advances in carrier technologies such as lipid nanoparticles (LNPs) and adeno-associated viruses (AAVs) are improving the in vivo delivery efficiency and targeting of Cas nucleases, expanding their applications in genetic disease and tumor treatment.

AI-assisted design: Machine learning models can predict Cas enzyme-DNA interactions, accelerating the development of highly active, less immunogenic variants, shortening R&D cycles and reducing costs.

This report aims to provide a comprehensive study of the global market for Cas Nuclease. Report Highlights:
(1) Global Cas Nuclease market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Cas Nuclease market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Cas Nuclease market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Cas Nuclease segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Cas Nuclease segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Cas Nuclease industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Cas9
Cpf1
Cas9n
Others

Market segment by Application, can be divided into
Gene Editing Cell Line Construction
Animal Models
Bioagriculture
Gene Therapy
Other

Market segment by players, this report covers
Thermo Fisher Scientific
GenScript
Integrated DNA Technologies, Inc.
Aldevron
Merck
Horizon Discovery
Agilent
OriGene Technologies, Inc
New England Biolabs
NIPPON GENE CO., LTD.
Novoprotein
Applied Biological Materials Inc. (abm)